Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Stem Cell Therapy | Q&As & Interviews

In Conversation with Stephen Sullivan, COO of iPSirius

Edited by Anya Chuykov | 30 April 2024
Cell & Gene 2024 Conference Producer Anya Chuykov met with Stephen Sullivan, COO of iPSirius, to discuss the advancements being made by iPSirius, and their unique proprietary technology working to treat aggressive forms of cancer.

Stephen shares insights into trends and challenges in the CGT space, and looks to Cell & Gene 2024 this November as an opportunity to connect with and address challenges with fellow key opinion leaders. Join the event to hear Stephen present on the Innovation & Collaboration track and discuss emerging modalities within the advanced therapy landscape on our C- & Executive level panel.

 

 

Speaker Biographies

Dr. Stephen Sullivan, Ph.D., M.B.A., a Fellow of the Royal Society of Medicine, brings expertise in Pluripotent Stem Cell-based therapies to iPSirius as its Chief Operating Officer and board member. With a rich background from prestigious institutions like Edinburgh and Harvard, he champions international quality standards and leverages his extensive network to fortify stakeholder relationships, ensuring iPSirius remains at the forefront of ATMP development.

Related Events

For more on this topic, you may be interested in our upcoming Cell 2025

Related Resources

The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine

The National Institute of Standards and Technology (NIST) has given $1.5 million to two organisations to enhance regenerative medicine standards.
Read More

Kyoto University Hospital Explores the Potential of Treating Type 1 Diabetes Using Induced Pluripotent Stem Cells

Kyoto University Hospital aims to develop a treatment for severe Type 1 diabetes using induced pluripotent stem cells (iPSCs) reprogrammed to function as pancreatic islet cells.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
01/11/24
Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing